Increased tumour necrosis factor α production in mesenteric lymph nodes of cirrhotic patients with ascites

Gut

Volumn 52, Issue 7, 2003, Pages 1054-1059

  Genesca J ^a   Marti R ^a   Rojo, F ^a   Campos, F ^a   Peribanez V ^a   Gonzalez A ^a   Castells, L ^a   Ruiz Marcellan C ^a   Margarit, C ^a   Esteban, R ^a   Guardia, J ^a   Segura, R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; INTERLEUKIN 6; MESSENGER RNA; PROTEIN; PROTHROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ASCITES; BACTERIAL INFECTION; BACTERIAL TRANSLOCATION; BACTERIUM DETECTION; BILIRUBIN BLOOD LEVEL; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTEROBACTERIACEAE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MESENTERY LYMPH NODE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE LEVEL;

ASCITES; BACTERIAL INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LIVER CIRRHOSIS; LYMPH NODES; MALE; MESENTERY; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038121788     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.7.1054     Document Type: Article

References (31)

1. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20:1359-63.
2. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
3. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-41.
4. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999;19:411-26.
5. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-91.
6. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide?. Lancet 1991;337:776-8.
7. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-57.
8. Mainous MR, Ertel W, Chaudry IH, et al. The gut: a cytokine-generating organ in systemic inflammation? Shock 1995;4:193-9.
9. Deitch EA. Role of the gut lymphatic system in multiple organ failure. Curr Opin Crit Care 2001;7:92-8.
10. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999;104:1223-33.
11. Genesca J, Gonzalez A, Segura R, et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999;94:169-77.
12. Lee FY, Lu RH, Tsai YT, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-α, and hyperdynamic circulation. Scand J Gastroenterol 1996;31:500-5.
13. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001;34:32-7.
14. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis 1997;17:203-17.
15. Garcia-Tsao G, Lee FY, Barden GE, et al. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995;108:1835-41.
16. Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis 1998;27:669-74.
17. Chu CJ, Lee FY, Wang SS, et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide. Clin Sci (Lond) 1997;93:219-25.
18. López-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-7.
19. López-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor α, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996;23:1616-21.
20. Lopez-Talavera JC, Levitzki A, Martinez M, et al. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J Clin Invest 1997;100:664-70.
21. Kawanaka H, Jones MK, Szabo IL, et al. Activation of eNOS in rat portal hypertensive gastric mucosa is mediated by TNF-alpha via the PI 3-kinase-Akt signaling pathway. Hepatology 2002;35:393-402.
22. Iwakiri Y, Tsai MH, McCabe TJ, et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol 2002;282:H2084-90.
23. Albornoz L, Motta A, Alvarez D, et al. Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relationship with hemodynamic disturbances. J Hepatol 2001;35:452-6.
24. Battista S, Bar F, Mengozzi G, et al. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997;26:75-80.
25. Perez-Paramo M, Muñoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000;31:43-8.
26. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrente in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-24.
27. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25:532-6.
28. Runyon BA, Borzio M, Young S, et al. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial, translocation, and survival in an animal model of cirrhosis. Hepatology 1995;21:1719-24.
29. Aparicio JR, Such J, Pascual S, et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol 1999;31:277-83.
30. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8.
31. Cereto F, Genesca J, Smithson A, et al. Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role? Eur J Gastroenterol Hepatol 2002;14:81-3.